BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly†, "the company†), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2025 of at least 17% year over year. Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2025 Revenue Growth of at least 17% Year over Year. Share About Butter ...

Core Viewpoint - AI is revolutionizing the drug development process in the biopharmaceutical industry, significantly enhancing efficiency and effectiveness in research and innovation [6][8]. Group 1: Human Evolution and Technological Revolution - The essence of humanity is rooted in its evolution from herbivorous to omnivorous diets, which has influenced societal traits and behaviors [2]. - Technological revolutions are identified as the core driving force of human development, following a cyclical pattern of slow incubation, rapid output, and eventual stagnation [4]. - Historical technological milestones include the Industrial Revolution initiated by Richard Arkwright in 1771, the steam engine by George Stephenson in 1852, and the advent of computers in 1939, culminating in the rise of artificial intelligence in the 1980s [4]. Group 2: Current Technological Waves - The world is currently experiencing overlapping technological waves, including the ongoing information network revolution and the emerging biopharmaceutical and AI waves [5]. - AI is reshaping social cognition and information dissemination, leading to changes in societal behaviors and decision-making processes [5]. Group 3: AI in Biopharmaceuticals - The integration of AI in biopharmaceuticals has led to the establishment of successful companies, with a notable success rate of 90% in projects initiated by the speaker's team [6]. - AI has significantly shortened drug development timelines, with three new drugs entering clinical phase II within six years, marking them as world-first innovations [8]. - The development of AI algorithms has enabled the standardization of biopharmaceutical data, expanding usable patient data from thousands to billions, thus enhancing the training of AI models [8].

Core Viewpoint - AI is revolutionizing the drug development process in the biopharmaceutical industry, significantly enhancing efficiency and effectiveness [10][14]. Group 1: Human Evolution and Technological Revolution - The essence of humanity is rooted in a plant-based diet, with a shift to meat consumption around three million years ago leading to significant evolutionary changes [4]. - Technological revolutions are the core narrative of human development, characterized by a cycle of slow incubation followed by rapid output and eventual stagnation [6][7]. - Historical technological revolutions include the Industrial Revolution, the rise of the automobile, and the advent of the internet, each marking significant economic and societal shifts [7]. Group 2: Current Technological Waves - The world is currently experiencing overlapping technological waves, including the ongoing information network revolution and the emerging biopharmaceutical and AI waves [8]. - AI is reshaping social cognition and information dissemination, leading to changes in societal behavior and decision-making processes [8]. Group 3: Biopharmaceutical Industry Insights - In 2022, China's biopharmaceutical industry achieved over $100 billion in external licensing, surpassing the export value of new energy vehicles, indicating a significant growth trajectory [8]. - Despite lower investment levels compared to the new energy vehicle sector, the biopharmaceutical field's growth reflects the irreversible nature of technological waves [8]. Group 4: AI in Drug Development - The integration of AI in biopharmaceuticals has led to the establishment of successful companies, with a 90% success rate in projects initiated by the speaker's team, resulting in 10 companies being launched [11]. - AI has drastically reduced drug development timelines, with three drugs entering clinical phase II within six years, marking them as "First-in-Class" innovations [14]. - AI algorithms have enabled the standardization of biopharmaceutical data, expanding usable patient data from thousands to billions, thus enhancing the training of AI models [14].

【导读】重磅嘉宾聚集2025资本市场香港论坛，热议科技与资管赋能高质量发展 12月19日，由中国基金报主办，摩根资产管理、慧博科技、安永支持的2025资本市场香港论坛（以下简 称论坛）举行。论坛主题为"科技与资管赋能高质量发展"，汇集约150位来自香港特区政府、境内知名 高校、科技企业、金融服务机构以及境内外资产管理机构的相关负责人、专业人士。与会嘉宾认为，A 股"慢牛"格局正在形成。2026年，全球范围内，科技依然是值得关注的主题。人工智能对医药行业的颠 覆正在发生。 本场论坛活动为紫荆文化集团主办的首届"香港国际AI艺术节"系列活动之一。本届艺术节于12月19日— 21日举行，以"预见未来：现实与无界"为主题，致力于打造亚洲首个聚焦技术与艺术深度融合的国际盛 事，助力香港建设国际创新科技中心与中外文化艺术交流中心，吸引了众多海内外顶尖科学家、艺术 家、企业代表及学界领袖参与。 香港财库局陈浩濂：2026年进一步落实举措 创建更高效、包容的市场环境 陈浩濂认为，资本市场的健康发展，离不开制度的不断完善。他表示，香港财库局正与香港证监会及香 港交易所紧密合作，检视及优化相关制度，包括缩短股票现货市场结算周期至 ...

Group 1 - The forum held on December 19, 2023, focused on "Technology and Asset Management Empowering High-Quality Development," gathering around 150 professionals from various sectors, indicating a growing interest in the integration of technology in finance and asset management [2] - The Hong Kong government is actively working to create a more efficient and inclusive market environment by optimizing regulations, including shortening the stock settlement cycle to T+1 and expanding acceptable collateral types [7][8] - AI is being widely applied across banking, securities, insurance, asset management, and green finance in Hong Kong, enhancing operational efficiency and enriching service ecosystems [7] Group 2 - AI is significantly transforming the drug development process, with advancements in machine learning and data analysis leading to faster and more efficient drug discovery [10][14] - The use of AI in biomedicine has improved the efficiency of drug development, with AI-driven companies achieving remarkable progress, including the entry of four drugs into clinical stages within six years [14] - AI's ability to standardize and process vast amounts of biomedical data has expanded the potential for training models, increasing usable patient data from thousands to billions [14] Group 3 - The A-share market is experiencing a "slow bull" trend, supported by institutional investment, corporate earnings, and lower-than-expected tariff risks, with technology innovation attracting both domestic and international investors [15][17] - Key themes for investment in 2026 include exports, AI, "anti-involution" in certain industries, and the consumer sector, with performance being a critical driver for market dynamics [17] - The insurance asset management sector is evolving with AI, moving from subjective decision-making to systematic optimization under complex constraints, enhancing decision quality and risk management [20][21]

Core Insights - Butterfly Network, Inc. is participating in the 8th Annual Evercore Healthcare Conference, with key executives scheduled for a fireside chat and one-on-one investor meetings [1][2] - The company is recognized for its innovative Ultrasound-on-Chip™ technology and has launched several handheld ultrasound systems, including the award-winning iQ3 [3][4] Company Overview - Butterfly Network, Inc. is a digital health company focused on transforming medical imaging through handheld, whole-body ultrasound technology and intuitive software solutions [1][3] - The company launched the first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by the iQ+ in 2020 and the iQ3 in 2024, each improving in processing power and performance [3] - The iQ3 received the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its significance in the healthcare sector [3] Product and Technology - Butterfly combines advanced hardware, intelligent software, AI, services, and education to enhance the adoption of affordable and accessible imaging solutions [4] - The company’s handheld ultrasound probes, paired with Compass™ enterprise workflow software, have been shown to improve care workflows, reduce costs, and enhance provider economics [4] - Butterfly's devices are available to trained healthcare practitioners globally, addressing critical healthcare challenges [4]

Core Insights - Butterfly Network has launched an AI-powered Gestational Age tool in Malawi and Uganda to enhance maternal and fetal health through improved access to ultrasound technology [1][4] - The tool allows lower-skilled healthcare workers to estimate gestational age quickly and accurately without requiring image interpretation or extensive training [4][5] - The initiative is part of Butterfly's broader commitment to advancing maternal health in under-resourced settings, supported by the Gates Foundation and developed in collaboration with the University of North Carolina [4][5] AI-Enabled Gestational Age Tool - The AI tool addresses the critical need for affordable ultrasound technology in low-resource settings, where 92% of maternal and neonatal mortality occurs in low- and middle-income countries [2] - It enables midwives and other healthcare providers to deliver timely care by determining the appropriate gestational age for necessary medical interventions [4] Milestone Achievements - Butterfly Network has successfully deployed 1,000 handheld ultrasound probes and trained over 1,050 healthcare providers in Sub-Saharan Africa from September 2022 to December 2024 [6] - As of July 2025, 1.8 million scans have been conducted, averaging 83,000 scans monthly, demonstrating significant integration of obstetrical ultrasound services in over 697 public health facilities [6] Positive Impact on Maternal Health - Preliminary data from Kenya indicates a significant increase in women seeking antenatal care before 24 weeks, with over 90% patient satisfaction reported [9] - In South Africa, there has been a notable reduction in stillbirths and maternal mortality, with 873 appropriate referrals made for higher-level care [10][11] - The average scan time for providers has been reduced to 1.3 minutes, with a high confidence level in detecting key maternal conditions post-training [12] Technological Advancements - The latest Butterfly device, iQ3, has been approved for use in South Africa and Kenya, enhancing the quality and accessibility of POCUS [7] - Butterfly's innovations have received multiple accolades, including the Best Medical Technology at the 2024 Prix Galien USA Awards, highlighting the company's commitment to advancing healthcare technology [14]

Core Insights - The study published in JAMA confirms that a Butterfly-enabled POCUS program focused on lung ultrasound significantly reduces hospital stay and costs associated with undifferentiated dyspnea, including acute heart-failure exacerbations [1][2][3]. Study Findings - The POCUS program led to a reduction of 246 hospital bed-days and resulted in direct cost savings of $751,537 during the evaluation period [3][4]. - The integration of a hospitalist POCUS workflow, which included lung ultrasound and AI assistance, was associated with a 30% reduction in expected hospital length of stay (8.3 days compared to 11.9 days, p = .01) [7]. - Clinical management was altered in 35% of cases due to the use of POCUS, highlighting its impact on patient care [7]. Economic Impact - The incremental cost-effectiveness ratio was calculated at $3,055 per hospital bed day saved, demonstrating the economic value of POCUS integration into inpatient care [7]. - The study emphasizes the potential for POCUS to improve hospital resource utilization and patient care through structured workflows [4][6]. Company Background - Butterfly Network, Inc. is a digital health company that specializes in portable ultrasound technology and software solutions, aiming to transform healthcare delivery [2][9]. - The company has developed a series of handheld ultrasound devices, including the Butterfly iQ, iQ+, and iQ3, which leverage advanced semiconductor technology [9][10].

Core Insights - The Medical Info Systems industry is experiencing significant growth driven by new federal policies and the $500 billion Stargate AI project initiated by Donald Trump, which aims to enhance AI infrastructure in healthcare [1][3][5] - The use of AI in the medical device market is projected to grow at a CAGR of 29.9% from 2026 to 2029, indicating strong demand for digital healthcare solutions [1][3] - The industry faces challenges due to escalating tariffs on imports, which could hinder the development of AI technologies essential for healthcare [2][5] Industry Overview - The Zacks Medical Info Systems industry includes companies that develop healthcare information systems, providing software and hardware solutions for secure access to clinical, administrative, and financial data [2] - The focus on patient satisfaction and data security has increased the demand for big data, cloud computing, blockchain, and AI technologies [2] Trends Influencing the Industry - AI is being increasingly adopted in the medical sector for drug synthesis, device creation, and diagnostics, with the global AI in healthcare market expected to reach $95.65 billion by 2025 [3] - Remote patient monitoring is growing rapidly due to the rise in wearable devices and telehealth services, with the global smart healthcare products market projected to grow from $145.9 billion in 2023 to $485.71 billion by 2032, at a CAGR of 12.78% [4] Financial Performance - The Zacks Medical Info Systems industry has underperformed the S&P 500 and the broader medical sector over the past year, with a decline of 6.6% compared to a 25.3% increase in the S&P 500 [9] - The industry is currently trading at a forward price-to-sales (P/S) ratio of 3.95, lower than the S&P 500's 4.56 and the sector's 2.50 [12] Investment Opportunities - Veeva Systems, with a Zacks Rank 1 (Strong Buy), is expected to see an 11% earnings growth for fiscal 2026 [18] - Hims & Hers Health, holding a Zacks Rank 2 (Buy), anticipates a 58% increase in earnings for 2025, driven by a growing subscriber base [22] - Butterfly Network, also with a Zacks Rank 2, projects a 5.9% improvement in earnings for 2025 [26]

Industry Overview - Healthcare IT spending is on the rise, with 75% of healthcare providers increasing investments in AI, cybersecurity, and other IT areas, transitioning from a pandemic response to a core aspect of next-generation healthcare driven by generative AI technologies [1][2] - The sector is projected to experience a compound annual growth rate (CAGR) of 15.4% from 2024 to 2031, making healthcare IT a highly attractive investment opportunity [2] Company Highlights - Tempus AI has seen its stock rise by 30% year-to-date, focusing on precision oncology and personalized care through its AI-based platform that integrates multi-modal data [7] - Butterfly Network is gaining traction with its Ultrasound-on-Chip technology and is expected to report 5.9% earnings growth alongside an 18.9% revenue increase in 2025, with a strong buy recommendation from brokers [12][13] - Health Catalyst provides data and analytics technology to improve healthcare outcomes, with expectations of 7.1% earnings growth and a 9.2% revenue increase in 2025, holding a "hold" rating from analysts [18][19] Digital Transformation - By 2025, 70% of healthcare leaders plan to invest in digital tools, with 60% aiming to upgrade core technologies like EMRs and ERP software, indicating a significant shift towards digital transformation in the industry [9] - Cybersecurity is a major focus, with 78% of executives prioritizing enhancements due to the increasing risk of cyber threats as digital adoption accelerates [10] Generative AI Impact - Over 40% of organizations report significant to moderate returns on investment from generative AI, while 37% are still evaluating its impact, suggesting many companies are in the early stages of implementation [11]